cTRL Therapeutics

San Francisco, United States Founded: 2022 • Age: 4 yrs
Solid tumor therapeutics are developed using magnetic-based cTRL technology.

About cTRL Therapeutics

cTRL Therapeutics is a company based in San Francisco (United States) founded in 2022 by Shana Kelley.. cTRL Therapeutics has raised $19.14 million across 2 funding rounds from investors including Intermountain Healthcare, FACIT and General Catalyst. cTRL Therapeutics offers products and services including cTRL-based Therapy and IsoQore™ Platform. cTRL Therapeutics operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Poseida Therapeutics and Immunocore, among others.

  • Headquarter San Francisco, United States
  • Founders Shana Kelley
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $19.14 M (USD)

    in 2 rounds

  • Latest Funding Round
    $9.14 M (USD), Seed

    Oct 10, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of cTRL Therapeutics

cTRL Therapeutics offers a comprehensive portfolio of products and services, including cTRL-based Therapy and IsoQore™ Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops polyclonal therapies using circulating T cells for solid tumors

Proprietary system for extracting tumor-reactive cells from blood

Funding Insights of cTRL Therapeutics

cTRL Therapeutics has successfully raised a total of $19.14M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $9.14 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Seed — $9.1M
  • First Round

    (10 Apr 2023)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2024 Amount Seed - cTRL Therapeutics Valuation

investors

Apr, 2023 Amount Seed - cTRL Therapeutics Valuation General Catalyst
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in cTRL Therapeutics

cTRL Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Intermountain Healthcare, FACIT and General Catalyst. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment and transformation services for entrepreneurs in technology and finance sectors.
Founded Year Domain Location
Invests in oncology startups, scales ventures, and drives clinical trials in Ontario.
Founded Year Domain Location
Healthcare services are delivered through integrated hospital networks.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by cTRL Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - cTRL Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Ctrl Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of cTRL Therapeutics

cTRL Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Poseida Therapeutics and Immunocore, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cell-based therapies for cancer treatment are developed.
domain founded_year HQ Location
Provider of cell therapies to treat cancer and hematologic conditions
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
domain founded_year HQ Location
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
domain founded_year HQ Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Ctrl Therapeutics

Frequently Asked Questions about cTRL Therapeutics

When was cTRL Therapeutics founded?

cTRL Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is cTRL Therapeutics located?

cTRL Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Who is the current CEO of cTRL Therapeutics?

Derrell Porter is the current CEO of cTRL Therapeutics.

Is cTRL Therapeutics a funded company?

cTRL Therapeutics is a funded company, having raised a total of $19.14M across 2 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Apr 10, 2023.

What does cTRL Therapeutics do?

cTRL Therapeutics was founded in 2022 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing cell therapies for solid tumors. Magnetic-based technology is utilized to target and activate cTRLs, a rare circulating T cell population in the blood, enabling engineered treatments against cancer. Operations center on enhancing therapeutic access for patients through this specialized approach.

Who are the top competitors of cTRL Therapeutics?

cTRL Therapeutics's top competitors include Immunocore, Juno Therapeutics and Janux Therapeutics.

What products or services does cTRL Therapeutics offer?

cTRL Therapeutics offers cTRL-based Therapy and IsoQore™ Platform.

Who are cTRL Therapeutics's investors?

cTRL Therapeutics has 4 investors. Key investors include Intermountain Healthcare, FACIT, General Catalyst, and FACIT.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available